ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Oklahoma » Pulmonary Disease

Top Pulmonary Disease Prescribers in Oklahoma

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
SANG LEE MD

Pulmonary Disease

15,744

$1.07M

701
395 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

22%
patients receiving schedule three controlled substances

Avg: 3%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 54%

$68
Average prescription price

Avg: $181

JOHNNY CHRISTIANSEN M.D.

Pulmonary Disease

6,927

$354K

298
251 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

20%
patients receiving schedule three controlled substances

Avg: 3%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 54%

$51
Average prescription price

Avg: $181

TALAT TAWAKLNA M.D.

Pulmonary Disease

6,023

$443K

371
270 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 54%

$73
Average prescription price

Avg: $181

BRIAN WHITSON M.D.

Pulmonary Disease

5,143

$593K

487
382 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 54%

$115
Average prescription price

Avg: $181

WILLIAM COOK M.D.

Pulmonary Disease

4,544

$881K

606
514 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

73%
prescriptions for brand name drugs

Avg: 54%

$194
Average prescription price

Avg: $181

IMTIAZ AHMED MD MCPS FACP FCCP

Pulmonary Disease

4,394

$350K

367
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 54%

$80
Average prescription price

Avg: $181

MAXIMO FERNAN MD

Pulmonary Disease

4,236

$311K

313
176 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 54%

$73
Average prescription price

Avg: $181

DAVID ALLEN M.D.

Pulmonary Disease

4,191

$607K

279
193 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 54%

$145
Average prescription price

Avg: $181

DENNIS PARKER MD

Pulmonary Disease

3,980

$795K

388
337 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 54%

$200
Average prescription price

Avg: $181

BRAD MARION M.D.

Pulmonary Disease

3,690

$575K

332
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

54%
prescriptions for brand name drugs

Avg: 54%

$156
Average prescription price

Avg: $181

RAVI MALPANI MD

Pulmonary Disease

3,682

$266K

257
201 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 54%

$72
Average prescription price

Avg: $181

ANDREW GOLDBERG MD

Pulmonary Disease

3,518

$869K

458
374 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 54%

$247
Average prescription price

Avg: $181

QASIM MIRZA M.D.

Pulmonary Disease

3,259

$3.23M

122
55 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 54%

$991
Average prescription price

Avg: $181

THOMAS PAPIN MD

Pulmonary Disease

3,162

$283K

238
160 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 54%

$90
Average prescription price

Avg: $181

GRACE KENNEDY DO

Pulmonary Disease

3,155

$729K

374
304 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

58%
prescriptions for brand name drugs

Avg: 54%

$231
Average prescription price

Avg: $181

MARK MYERS MD

Pulmonary Disease

2,868

$720K

391
329 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 54%

$251
Average prescription price

Avg: $181

MARK FIXLEY M.D.

Pulmonary Disease

2,802

$681K

476
426 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 54%

$243
Average prescription price

Avg: $181

AZHAR KHAN MD

Pulmonary Disease

2,738

$444K

366
292 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 54%

$162
Average prescription price

Avg: $181

JOEL SABANGAN MD

Pulmonary Disease

2,677

$264K

272
199 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 54%

$99
Average prescription price

Avg: $181

NANCY NAGLE MD

Pulmonary Disease

2,448

$382K

287
218 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 54%

$156
Average prescription price

Avg: $181

ARUN DEVAKONDA MD

Pulmonary Disease

2,411

$355K

362
240 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 54%

$147
Average prescription price

Avg: $181

WALTER BOOMER MD

Pulmonary Disease

2,411

$1.2M

331
268 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

74%
prescriptions for brand name drugs

Avg: 54%

$498
Average prescription price

Avg: $181

NADIM DAHER MD

Pulmonary Disease

2,220

$245K

195
145 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 54%

$111
Average prescription price

Avg: $181

MOHAMMAD PARACHA M.D.

Pulmonary Disease

2,081

$294K

276
195 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 54%

$141
Average prescription price

Avg: $181

FRED GARFINKEL M.D.

Pulmonary Disease

1,996

$451K

227
180 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 54%

$226
Average prescription price

Avg: $181

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank